176 related articles for article (PubMed ID: 37461133)
21. Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function.
Sella A; Kovel S
Int Braz J Urol; 2012; 38(1):49-56. PubMed ID: 22397786
[TBL] [Abstract][Full Text] [Related]
22. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
Gupta S; Kamat AM
Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305
[TBL] [Abstract][Full Text] [Related]
23. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
[TBL] [Abstract][Full Text] [Related]
24. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Song Y; Yang L; Zhou A; Chi Y; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Terakawa T; Miyake H; Yokoyama N; Miyazaki A; Tanaka H; Inoue T; Fujisawa M
Urol Int; 2014; 92(2):180-5. PubMed ID: 24246751
[TBL] [Abstract][Full Text] [Related]
26. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
Sternberg CN; Skoneczna IA; Castellano D; Theodore C; Blais N; Voog E; Bellmunt J; Peters F; Le-Guennec S; Cerbone L; Risse ML; Machiels JP
Oncology; 2013; 85(4):208-15. PubMed ID: 24080920
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Halim A; Abotouk N
Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
29. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.
Park JH; Lee SW; Kim HS; Kang SG; Ko YH; Kim ST; Kang SH; Park YJ; Choi IK; Oh SC; Sung DJ; Seo JH; Cheon J; Kim YH; Kim JS; Park KH
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1033-9. PubMed ID: 23370665
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
31. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Ramos JD; Casey MF; Crabb SJ; Bamias A; Harshman LC; Wong YN; Bellmunt J; De Giorgi U; Ladoire S; Powles T; Pal SK; Niegisch G; Recine F; Alva A; Agarwal N; Necchi A; Vaishampayan UN; Rosenberg JE; Galsky MD; Yu EY;
Cancer Med; 2017 Jan; 6(1):186-194. PubMed ID: 28000388
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
33. Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
Tsang ES; Forbes C; Chi KN; Eigl BJ; Parimi S
Curr Oncol; 2019 Apr; 26(2):e260-e265. PubMed ID: 31043835
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
[TBL] [Abstract][Full Text] [Related]
35. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Tully CM; Apolo AB; Zabor EC; Regazzi AM; Ostrovnaya I; Furberg HF; Rosenberg JE; Bajorin DF
Cancer; 2016 Mar; 122(5):712-21. PubMed ID: 26618338
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG
Oncology; 2017; 93(1):36-42. PubMed ID: 28399521
[TBL] [Abstract][Full Text] [Related]
37. [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Helke C; May M; Hoschke B
Aktuelle Urol; 2006 Sep; 37(5):363-8. PubMed ID: 17004181
[TBL] [Abstract][Full Text] [Related]
38. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
Foerster B; Abufaraj M; Petros F; Azizi M; Gupta M; Schweitzer D; Margulis V; Iwata T; Kimura S; Shabsigh A; Briganti A; Ku JH; Muilwijk T; Kassouf W; Matin SF; Spiess PE; Pierorazio PM; Hendricksen K; Shariat SF;
J Urol; 2020 Jun; 203(6):1101-1108. PubMed ID: 31898919
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]